Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Receivables (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Receivables for 6 consecutive years, with $62.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables rose 3.17% year-over-year to $62.5 million, compared with a TTM value of $62.5 million through Dec 2025, up 3.17%, and an annual FY2025 reading of $62.5 million, up 3.17% over the prior year.
  • Receivables was $62.5 million for Q4 2025 at Cytek Biosciences, up from $56.6 million in the prior quarter.
  • Across five years, Receivables topped out at $62.5 million in Q4 2025 and bottomed at $24.0 million in Q2 2021.
  • Average Receivables over 5 years is $46.5 million, with a median of $49.6 million recorded in 2023.
  • The sharpest move saw Receivables skyrocketed 75.16% in 2021, then decreased 10.04% in 2024.
  • Year by year, Receivables stood at $29.8 million in 2021, then surged by 64.19% to $48.9 million in 2022, then grew by 14.46% to $55.9 million in 2023, then rose by 8.33% to $60.6 million in 2024, then grew by 3.17% to $62.5 million in 2025.
  • Business Quant data shows Receivables for CTKB at $62.5 million in Q4 2025, $56.6 million in Q3 2025, and $56.2 million in Q2 2025.